Amiodarone
Amiodarone is an antiarrhythmic medicine. Its US labels describe two forms: tablets (Pacerone is a US brand) and an injection (Nexterone). The tablet label lists documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable ventricular tachycardia in adults who have not responded to other available antiarrhythmics or cannot tolerate them. The injection label lists treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. The tablet label carries a boxed warning: the medicine is intended only for the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, and it can cause lung toxicity, liver toxicity that can be fatal, and worse arrhythmias. Cordarone, the brand approved in 1985 under NDA018972, is listed as discontinued.
Also called Pacerone · Nexterone · Cordarone
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 703 (amiodarone); UNII 976728SY6Z is the UNII of the salt, amiodarone hydrochloride, that the labels give, so it is a broad match; US drug-label class Antiarrhythmic (established pharmacologic class, RxClass). Labels read: Pacerone tablets (Upsher-Smith, abbreviated application ANDA075135, effective 2025-07-14) and Nexterone injection (Baxter, NDA022325, effective 2024-04-16). Other openFDA amiodarone labels, from generic and repackager sponsors, were listed and not used. Cordarone tablets (Wyeth, NDA018972) are listed in Drugs@FDA with marketing status Discontinued; the original approval is dated 1985-12-24, classified as a Type 1 new molecular entity with priority review. The tablet indication sentence says "unstable tachycardia" without the word ventricular; the Highlights line of the same label names ventricular tachycardia. Neither label lists atrial fibrillation, atrial flutter or supraventricular tachycardia. This page records label statements and the class only: no trial result and no dose is recorded.
Trials at a glance
The figures count the 20 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 20
- Phase 3 or 4
- 19
- Recruiting
- 3
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 1 | 0 | 1 |
| Phase 3 | 2 | 1 | 3 | 6 | 12 |
| Phase 4 | 1 | 2 | 0 | 4 | 7 |
| All phases | 3 | 3 | 4 | 10 | 20 |
Conditions these trials study
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Sudden cardiac arrest
- Atrial flutter
- Cardiomyopathy (heart muscle disease)
- Ventricular tachycardia
Sponsors with the most trials
- Elsan
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Fundación Cardioinfantil Instituto de Cardiología
- Icahn School of Medicine at Mount Sinai
- Institut Investigacio Sanitaria Pere Virgili
About this drug
- Level
- Substance
- Mechanism
- The label says amiodarone is considered a class III antiarrhythmic drug but has electrophysiologic characteristics of all four Vaughan Williams classes.
Classification codes
-
976728SY6ZAmiodarone hydrochloride
Claims and evidence
Context Adults for whom the US label of amiodarone tablets (Pacerone) lists an indication: life-threatening recurrent ventricular fibrillation or recurrent hemodynamically unstable ventricular tachycardia
- Recipient
- Adult
- Population
- Adults described in the indications section of the label; the indication sentence is written for adults.
- Care setting
- Prescription medicine in tablet form, as described in the US label; the boxed warning says to initiate it in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adults with documented, life-threatening recurrent ventricular fibrillation
- Adults with life-threatening recurrent hemodynamically unstable ventricular tachycardia
- Adults who have not responded to adequate doses of other available antiarrhythmics or who cannot tolerate alternative agents
- Excluded
- None stated
The US label of Pacerone (amiodarone hydrochloride tablets, Upsher-Smith), in the version dated 14 July 2025 in openFDA, lists the tablets for documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. The Highlights lines of the label name recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. The label carries a boxed warning titled pulmonary, hepatic and cardiac toxicity. It says the medicine is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, that it can cause pulmonary toxicity and liver toxicity that can be fatal, and that it can exacerbate arrhythmias.
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the main lines of the boxed warning and the first sentence on mechanism were read; contraindications, doses, interactions and other warnings were not recorded. The label sentence says "unstable tachycardia" without the word ventricular; the ventricular wording is in the Highlights line. Labels change: openFDA also lists repackager copies and other amiodarone labels with other text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (10)
-
- Locator
- results[0].indications_and_usage[0], 1, sentence 1, fragment 1 of 2
- How it applies
- Indication, first part.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1, sentence 1, fragment 2 of 2
- How it applies
- Indication, second part: adults and the condition on prior therapy.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1, highlights, item 1
- How it applies
- Highlights line: ventricular fibrillation.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1, highlights, item 2
- How it applies
- Highlights line: ventricular tachycardia.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Title of the boxed warning.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], sentence 1
- How it applies
- First sentence of the boxed warning.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], pulmonary
- How it applies
- Pulmonary toxicity statement in the boxed warning.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], hepatic
- How it applies
- Liver toxicity statement in the boxed warning (the label spells the word hepatoxicity).
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], cardiac
- How it applies
- Arrhythmia statement in the boxed warning.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250714.
- Retrieved
- Source effective date
- 2025-07-14
- Source state
- Current
- Version fingerprint
634bb6709ac6c7617c0112368b9bc30cf00ea37e42a72ee3e2302b2ee7725e3b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients refractory to other therapy for whom the US label of amiodarone injection (Nexterone) lists an indication: frequently recurring ventricular fibrillation or hemodynamically unstable ventricular tachycardia
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label sentence gives no age range.
- Care setting
- Prescription medicine given as an injection, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with frequently recurring ventricular fibrillation who are refractory to other therapy
- Patients with hemodynamically unstable ventricular tachycardia who are refractory to other therapy
- Excluded
- None stated
The US label of Nexterone (amiodarone injection, Baxter), in the version dated 16 April 2024 in openFDA, lists the injection for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.
Applies to Recipient not specified Patients refractory to other therapy for whom the US label of amiodarone injection (Nexterone) lists an indication: frequently recurring ventricular fibrillation or hemodynamically unstable ventricular tachycardia
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the first indication sentence was read; the record has no boxed warning field, and warnings, doses and interactions were not read. Labels change, and openFDA lists other injection labels with other text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports openFDA drug label record for Nexterone (amiodarone injection), Baxter label: indications
- Locator
- results[0].indications_and_usage[0], 1, sentence 1, fragment 1 of 2
- How it applies
- Indication, first part.
- Retrieved
- Source effective date
- 2024-04-16
- Source state
- Current
- Version fingerprint
bb5fd04fceab84988417e394dd950279d8e65de001585c3bffe5b92e1c663231- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record for Nexterone (amiodarone injection), Baxter label: indications
- Locator
- results[0].indications_and_usage[0], 1, sentence 1, fragment 2 of 2
- How it applies
- Indication, second part: ventricular tachycardia and prior therapy.
- Retrieved
- Source effective date
- 2024-04-16
- Source state
- Current
- Version fingerprint
bb5fd04fceab84988417e394dd950279d8e65de001585c3bffe5b92e1c663231- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Background openFDA drug label record for Nexterone (amiodarone injection), Baxter label: indications
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20240416.
- Retrieved
- Source effective date
- 2024-04-16
- Source state
- Current
- Version fingerprint
bb5fd04fceab84988417e394dd950279d8e65de001585c3bffe5b92e1c663231- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context United States approval record NDA018972 for Cordarone (amiodarone hydrochloride tablets)
- Recipient
- Recipient not specified
- Population
- Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication.
- Care setting
- Not stated in the FDA record
- Geography
- United States (decision by the US Food and Drug Administration)
- Life stage
- Not stated in the FDA record
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The openFDA Drugs@FDA record for New Drug Application NDA018972 names WYETH PHARMS as sponsor and lists one product, CORDARONE tablets (amiodarone hydrochloride), with marketing status Discontinued. It lists the original approval as submission ORIG-1, with status date 24 December 1985, classified as Type 1 - New Molecular Entity, with priority review.
Applies to Recipient not specified United States approval record NDA018972 for Cordarone (amiodarone hydrochloride tablets)
- Certainty method
- Not assessed
- Limitations
- This claim records the original approval and the status the record gives, as of the fetch date. The record carries no indication text for the original approval, so it does not say what the medicine was approved to treat in 1985. It lists many later supplements. A discontinued status says the product is not marketed under this application; it is not a finding about safety or effectiveness. An approval is not a finding about how well the medicine works. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].application_number
- How it applies
- The application number of this record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].sponsor_name
- How it applies
- The application sponsor, as the record writes the name.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].products[0].brand_name
- How it applies
- The product brand name.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].products[0].marketing_status
- How it applies
- The product marketing status.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].submissions[27].submission_type
- How it applies
- The original submission.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].submissions[27].submission_status_date
- How it applies
- The original approval status date, in compact form.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].submissions[27].submission_class_code_description
- How it applies
- The submission classification of the original approval.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA018972 (CORDARONE, amiodarone hydrochloride tablets)
- Locator
- results[0].submissions[27].review_priority
- How it applies
- The review priority of the original approval.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
92c954cf9ed6c46ab0fafd51aff46801c841dfa1f05982f98d47d36ffe7d713d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
AMIODARONE HYDROCHLORIDE
No label from the application holder was found in the openFDA label dataset for application NDA021594. This page does not show another labeler's label in its place.
CORDARONE
No label from the application holder was found in the openFDA label dataset for application NDA018972. This page does not show another labeler's label in its place.
CORDARONE
No label from the application holder was found in the openFDA label dataset for application NDA020377. This page does not show another labeler's label in its place.
NEXTERONE
No label from the application holder was found in the openFDA label dataset for application NDA022325. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact The US tablet label lists recurrent hemodynamically unstable ventricular tachycardia: Ventricular tachycardia
The US label of Pacerone (amiodarone hydrochloride tablets, Upsher-Smith), in the version dated 14 July 2025 in openFDA, lists the tablets for documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. The Highlights lines of the label name recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. The label carries a boxed warning titled pulmonary, hepatic and cardiac toxicity. It says the medicine is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, that it can cause pulmonary toxicity and liver toxicity that can be fatal, and that it can exacerbate arrhythmias.Limitations. This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the main lines of the boxed warning and the first sentence on mechanism were read; contraindications, doses, interactions and other warnings were not recorded. The label sentence says "unstable tachycardia" without the word ventricular; the ventricular wording is in the Highlights line. Labels change: openFDA also lists repackager copies and other amiodarone labels with other text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 4
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 20
Record details
- Record id
cardio:amiodarone- Content hash
51943232d4885d18223dda4bfc0b5b77b6908c70cb241d98c96621e942e9e28f